(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 June 2002 (06.06.2002)

PCT

(10) International Publication Number
WO 02/44151 A1

(51) International Patent Classification[7]: C07D 209/48, A61K 31/40, A61P 13/08

(21) International Application Number: PCT/IB01/02261

(22) International Filing Date:
29 November 2001 (29.11.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
1097/DEL/2000 30 November 2000 (30.11.2000) IN

(71) Applicant *(for all designated States except US)*: **RANBAXY LABORATORIES LIMITED** [IN/IN]; 19, Nehru Place, New Delhi 110 019 (IN).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **ANAND, Nitya** [IN/IN]; B-62, Nirala Nagar, Lucknow 226 007, Uttar Pradesh (IN). **JAIN, Sanjay** [IN/IN]; Flat No. 3, 1st Floor, Madhav Residency, Marutra, Gayekvad Nagar, 7 Aundh, Pune (IN). **SINHA, Neelima** [IN/IN]; D-5, DSIR Colony, Nirala Nagar, Lucknow 226 007, Uttar Pradesh (IN). **CHUGH, Anita** [IN/IN]; RA-36, Inder Puri, New Delhi 110 012 (IN). **HEGDE, Laxminarayan, G.** [IN/IN]; 790, Sector-A, Pocket-C, Vasant Kunj, New Delhi 110 070 (IN). **GUPTA, Jang, Bahadur** [IN/IN]; 349, Sector-14, Gurgaon 122 001, Haryana (IN).

(74) Common Representative: **DESHMUKH, Jayadeep, R.**; Ranbaxy Laboratories Limited, 600 College Road East, Suite 2100, Princeton, NJ 08540 (US).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.

(84) Designated States *(regional)*: ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report*
before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 02/44151 A1

(54) Title: 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE SG(A)1-ADRENOCEPTOR BLOCKERS

(57) Abstract: The present invention relates to a novel 1,4-disubstituted piperazine derivatives of Formula I, and their pharmaceutically acceptable acid addition salts having excellent uro-selective α1-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating the symptoms of benign prostatic hyperplasia (BPH). The invention also relates to methods for making the novel compounds, pharmaceutical compositions containing the compounds, and method of treating the symptoms of benign prostatic hyperplasia using the compounds.

1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES USEFUL AS URO-SELECTIVE ALPHA$_1$-ADRENOCEPTOR BLOCKERS

FIELD OF THE INVENTION

The present invention relates to certain novel 1,4-disubstituted piperazine derivatives of Formula I,



FORMULA - I

and their pharmaceutically acceptable acid addition salts having excellent uro-selective α_1-adrenoceptor antagonistic activity exceeding those of previously described compounds. The compounds of the present invention hold promise for treating the symptoms of benign prostatic hyperplasia (BPH). The invention also relates to methods for making the novel compounds, pharmaceutical compositions containing the compounds, and method of treating the symptoms of benign prostatic hyperplasia using the compounds.

BACKGROUND OF THE INVENTION

Benign prostatic hyperplasia (BPH) is a common disease in aging males and a substantial percentage of men with BPH develop a bladder obstruction. The obstruction caused by BPH is thought to be attributable to two main components i.e. a static component related to enlarged prostatic tissue mass and a dynamic component involving excessive contraction of prostate and urethra. The most successful therapies are based on α-

adrenergic receptor antagonism and androgen levels modulation by 5α-reductase inhibitors. 5α-reductase inhibitors are of limited effectiveness in terms of immediate symptomatic and urodynamic relief. α_1-adrenergic receptors antagonists appear to be much more effective and provide immediate subjective symptomatic improvements and are, therefore, the preferred modalities of treatment in the control of symptoms of benign prostatic hyperplasia. α_1-Adrenoceptors are also present in blood vessels and play an important role in the regulation of blood pressure. Thus α_1-adrenoceptor antagonists are of particular importance as they were originally developed as antihypertensive agents and are likely also to have a beneficial effect on lipid dysfunction and insulin resistance, which are commonly associated with essential hypertensions.

The drugs most often used for BPH are the long acting α_1-adrenoceptor antagonists, terazosin, doxazosin and tamsulosin, as shown below:



TERAZOSIN



DOXAZOSIN



(R)-(-)-TAMSULOSIN

However, these drugs are associated with vascular side effects (e.g. postural hypertension, syncope, dizziness, headache etc.) due to lack of selectivity of action between prostatic and vascular α_1-adrenoceptors.

Over the past decade, there has been an intensive search for "uroselective" α_1-adrenoceptor antagonists for BPH, which would avoid the cardiovascular side effects, associated with currently used drugs. Clearly, α_1-adrenoceptor antagonists which have inherently greater selectivity for prostatic α_1-adrenoceptors offer the potential of increased urodynamic benefits. This underscores the importance of the discovery of antagonists which will confer urodynamic improvement without the side effects associated with exlsting drugs.

Recently, three subtypes of α_1-receptors namely α_{1A}, α_{1B}, and α_{1D} have been identified which can provide a key development to improve the pharmacological selectivity of α_1 blockers. These subtypes have different tissue distribution with the α_{1A} receptors predominating lower urinary tract tissue and less prevalent in the vasculature. This makes it possible to develop agents with selective action against pathological urodynamic states. A uroselective α_{1A}-antagonist could have greater efficacy if dose escalation is not limited to cardiovascular side effects and a more complete blockade of prostatic α_1-adrenoceptors could be attained. Compounds have been evaluated for potency against agonist or stimulation-induced increase in urethral pressure relative to blood pressure reduction or blockade of agonist-induced blood pressure. Many selective antagonists have been described by Hieble et al in Exp opin Invest Drugs; 6, 367-387 (1997) and by Kenny et. al. in J. Med. Chem.; 40, 1293 - 1315 (1997). Structure activity relationships in many of these structural series have been studied in details and numerous highly selective compounds have been identified.

The present invention is directed to the development of novel α_1-antagonists, namely, 1,4-disubstituted piperazine compounds, with greater selectivity of action against α_{1A}-adrenoceptors and which would thus offer relief from the symptoms of BPH.

There are many description in the literature about the pharmacological activities associated with phenyl piperazines, Eur. J. Med. Chem. - Chimica Therapeutica, 12, 173-176 (1977), describes substituted trifluoromethyl phenyl piperazines having cyclo-imido alkyl side chains shown below.



These compounds are potential anorectic agents with no CNS side effects. Other related compounds which have been prepared as anxiolytic, neuroleptic, anti-diabetic and anti-allergic agents are described in the following references:

- Yukihiro et al; PCT Appl. WO 98/37893 (1998).
- Steen et al; *J. Med. Chem.*, 38, 4303-4308 (1995).
- Ishizumi et al. *Chem. Pharm. Bull*, 39 (9), 2288-2300 (1991).
- Kitaro et al; JP 02-235865 (1990).
- Ishizumi et al; US 4,598,078 (1986).
- New et. al; J. Med. Chem, 29, 1476-1482 (1986).
- Shigeru et al, JP 60-204784 (1985).
- New et al, US 4,524,206 (1985).
- Korgaonkar et al; *J. Indian Chem. Soc.*, 60, 874-876 (1983)

The synthesis and pharmacology of some 2-[3-(4-aryl-1-piperazinyl) propyl]-1H-benz(de) isoquinolin-1,3-(2H)-diones/2,5-pyrrolidinediones (J. Indian. Chem. Soc., Vol., LXIII, 529-530 (1986), of N-(N^4-aryl-N^1-piperozinylmethyl)-4-(4-methoxyphenyl)piperidine-2,6-diones [J. Indian Chem. Soc., Vol. LV, 819-821 (1978)], and of N- (N^4-arylpiperazinylalkyl)-phthalimides (J. Indian. Chem. Soc., Vol. LVI, 1002-1005 (1979)] have been reported. The compounds were shown to exhibit antihypertensive and CNS depressant activity in experimental animals.

However, none of the above mentioned references disclose or suggest the selective α_1 -adrenoceptor blocking activity of the compounds disclosed therein and thus their usefulness in the treatment of symptoms of benign prostate hyperplasia did not arise.

The synthesis of 1-(4-arylpiperazin-1-yl)-ω-[N-(α, ω-dicarboximido)]-alkanes useful as uro-selective α_1-adrenoceptor blockers are disclosed in US Patent Nos. 6,083,950 and 6,090,809. These compounds had good α_1-adrenergic blocking activity and selectivity and one of the compounds is in phase II clinical trials.

It has now been discovered that structural modification of these compounds from glutarimide to tetrahydrophthalimide enhances the adrenoceptor blocking acitvity and also greatly increases the selectivity for α_{1A} in comparison to α_{1B} - adrenoceptor blocking activity, an essential requirement for compounds to be good candidates for treatment of BPH.

OBJECTS OF THE INVENTION

An object of the present invention is to provide novel arylpiperazine derivatives that exhibit greater α_{1A}-adrengeric blocking potency and more selectivity than available known compounds and are useful for treatment of benign prostatic hyperplasia.

It Is also an object of the invention to provide a method for synthesis of the novel compounds.

It is a further object of the present invention to provide compositions containing the novel compounds which are useful in the treatment of benign prostatic hyperplasia.

SUMMARY OF THE INVENTION

The above-mentioned objectives are achieved by a novel class of piperazine derivatives of general Formula I, as shown below,



FORMULA - I

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6

alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro and trifluoroalkoxy group, or (dihalodiphenyl) methyl.

Halogen of Formula I may be selected from the group consisting of chloro, fluoro, Iodo; C_1-C_6 alkyl may be selected from methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl; and C_1-C_6 alkoxy may be selected from methoxy, ethoxy, n-propoxy, isopropoxy, or hexyloxy.

The present invention also provides pharmaceutical compositions for the treatment of benign prostatic hyperplasia. These compositions comprise an effective amount of at least one of the compounds of Formula I, or an effective amount of at least one physiologically acceptable acid addition salt thereof, with a pharmaceutically acceptable carrier.

An illustrative list of particular compounds of the invention is given below:

Compound No.	Name
1.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
2.	2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
3.	2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
4.	2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
5.	2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

No.	Name
6.	2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
7.	2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
8.	2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
9.	2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
10.	2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoIndole-1,3(2H)-dione;
11.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
12.	2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoIndole-1,3(2H)-dione;
13.	2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
14.	2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
15.	2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
16.	2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
17.	2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
18.	2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
19.	2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
20.	2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
21.	2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

No.	Name
22.	2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
23.	2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
24.	2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
25.	2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
26.	2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
27.	2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
28.	2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
29.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
30.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;
31.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione;

DETAILED DESCRIPTION OF THE INVENTION

The compounds of the present invention may be prepared by one of the reaction sequences (Schemes I and II) shown below to yield compounds of Formula I wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group

consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro and trifluoroalkoxy group, or (dihalodiphenyl) methyl.

Scheme I

The compounds of the Formula I can be prepared by condensation of piperazine derivatives of Formula III with the anhydride of Formula II, wherein A and R are the same as defined above, preferably in a solvent selected from the group consisting of pyridine, n-butanol, benzene and xylene while refluxing.

SCHEME - I



FORMULA II **FORMULA III**

Solvent, Δ



FORMULA I

Scheme II

The compounds of the Formula I, wherein A and R are the same as defined above, can also be synthesized following the reaction sequence as shown in Scheme II, by condensation of 1-(ω-haloalkyl)-cis-3a,4,7,7a-tetrahydrophthalimide of Formula IV, wherein A is the same as defined above, with 1-substituted piperazine of the Formula V, wherein R is the same as defined before.

SCHEME - II



FORMULA IV **FORMULA V**





FORMULA I

Pharmaceutically acceptable, non toxic, acid addition salts of the compounds prepared according to the present invention having the utility of the free bases of Formula I may be formed with inorganic or organic acids, by methods well known in the art and may be used in place of the free bases. Representative examples of suitable acids for formation of such acid addition salts are malic, fumaric, benzoic, ascorbic, pamoic, succinic, bismethylene, salicylic, methanesulphonic ethanedisulphonic, acetic, propionic, tartaric, citric, gluconic, aspartic, stearic , palmitic, itaconic, glycolic, p-aminobenzoic, glutamic, benzenesulfamic, phosphoric, hydrobromic, sulfuric, hydrochloric, and nitric acids, and the like.

The present invention also includes within its scope prodrugs of the compounds of Formula I. In general, such prodrugs will be functional derivatives of these compounds which are readily converted in vivo into the defined compounds. Conventional procedures for the selection and preparation of suitable prodrugs are known.

The invention also includes the enantiomers, diastereomers, N-oxides, pharmaceutically acceptable salts, amides and polymorphic forms of these compounds, as well as metabolites having the same activity. The invention further includes pharmaceutical compositions comprising the molecules of Formula I, or prodrugs, metabolites, enantiomers, diastereomers, N-oxides, pharmaceutically acceptable salts or polymorphic forms thereof, in combination with a pharmaceutically acceptable carrier and optionally included excipients.

In yet another aspect, the invention is directed to methods for selectively blocking α_{1A} receptors by delivering in the environment of said receptors, e.g. to the extracellular medium (or by administering to a mammal possessing said receptors) an effective amount of the compounds of the invention.

While the invention has been described by reference to specific embodiments, this was for purposes of illustration only. Numerous alternative embodiments will be apparent to those skilled in the art and are deemed to be within the scope of the invention.

The examples mentioned below demonstrate the general synthetic as well as the specific preparation for the preferred compound. The examples are given to illustrate the details of the invention and should not be constrained to limit the scope of the present invention.

EXAMPLE

Preparation of 2-[3-{4-(2-methoxyphenyl)piperazine-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione.

Scheme I

A mixture of 1-amino-3-[4-(2-methoxyphenyl)piperazine-1-yl]propane (0.498g, 2.0 mmol) and cis-1,2,3,6-tetrahydrophthalic anhydride (0.273g, 1.8mmol) was refluxed in pyridine (10ml) for about 5 hrs. After the reaction was over, solvent was removed under vacuum and the residue was dissolved in chloroform (25ml). The chloroform phase was washed with water (2 x

15ml), dried over anhydrous sodium sulphate and concentrated under vacuum. The crude compound so obtained was purified by column chromatography over silica gel (100-200 mesh) using chloroform as an eluent (yield = 0.502g, 72%).

The hydrochloride salt was prepared by the addition of molar quantity of ethereal hydrogen chloride solution to the etheral solution of free base and collected the precipitated solid by filtration (m.p. 184-185ºC).

Scheme II

A mixture of 1-(3-bromopropyl)-cis-3a, 4,7,7a-tetrahydrophthalimide (7.04g, 25.88 mmol), 1-(2- methoxyphenyl)piperazine hydrochloride (5.32g, 23.29 mmol), potassium carbonate (7.14g, 51.76mmol) and potassium iodide (0.026g, 1.55mmol) in N, N-dimethylformamide (27ml) was heated at 75-80ºC for about 12 hours. After the reaction was over, solvent was evaporated under vacuum, residue was suspended in water (130ml) and extracted the compound with dichloromethane (2 x 65ml). The combined dichloromethane layer was washed with water (2 x 30ml), dried over anhydrous sodium sulphate and concentrated the solvent under vacuum to yield 8.308g (93%) of the crude base. The compound so obtained was converted into its hydrochloride salt (m. pt. 184-185ºC).

An illustrative list of the compounds of the invention which were synthesised by one or more of the above described methods is now given.

Compound No.	Name
1.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 184-185ºC.
2.	2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 221-223ºC.
3.	2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 186-187ºC.
4.	2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 228-230ºC.
5.	2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 215-217ºC.
6.	2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 203-204ºC.
7.	2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 194-196ºC.
8.	2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 163-165ºC.
9.	2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 232.5-233.5ºC.
10.	2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 218.2-219ºC.
11.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-Isoindole-1,3(2H)-dione hydrochloride; m.p. 221.9 - 222.7ºC.
12.	2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 231-232ºC.
13.	2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 231-232ºC.
14.	2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.275-276ºC.
15.	2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.263-265ºC.

No.	Name
16.	2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.259.5 - 261ºC.
17.	2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.248-249ºC.
18.	2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.232-233ºC.
19.	2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.235-236ºC.
20.	2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.210-211ºC.
21.	2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.226-227ºC.
22.	2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.223-224ºC.
23.	2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.223-224ºC.
24.	2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.193-194ºC.
25.	2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.165-166ºC.
26.	2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 193-195ºC.
27.	2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 264-265ºC.
28.	2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.267-268ºC.
29.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.219-220ºC.
30.	2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p. 184-185ºC.
31.	2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione hydrochloride; m.p.246-248ºC.

All the melting points reported above are uncorrected and measured by an open capillary method using Buchi 535.

PHARMACOLOGICAL TESTING RESULTS

Receptor Binding Assay

Receptor binding assays were performed using native α-adrenoceptors. The affinity of different compounds for α_{1A} and α_{1B} adrenoceptor subtypes was evaluated by studying their ability to displace specific [^{3}H]prazosin binding from the membranes of rat submaxillary and liver respectively *(Michel et al, Br J Pharmacol, 98, 883-889 (1989)).* The binding assays were performed according to *U'Prichard et al.(Eur J Pharmacol, 50:87-89 (1978))* with minor modifications.

Submaxillary glands were isolated immediately after sacrifice. The liver was perfused with buffer (Tris HCl 50 mM, NaCl 100 mM ,10 mM EDTA pH 7.4). The tissues were homogenised in 10 volumes of buffer (Tris HCl 50 mM, NaCl 100 mM, EDTA 10 mM, pH 7.4). The homogenate was filtered through two layers of wet gauze and filtrate was centrifuged at 500g for 10min. The supernatant was subsequently centrifuged at 40,000g for 45 min. The pellet thus obtained was resuspended in the same volume of assay buffer (Tris HCl 50 mM, EDTA 5mM, pH 7.4) and were stored at -70°C until the time of assay.

The membrane homogenates (150-250 µg protein) were incubated in 250 µl of assay buffer (Tris HCl 50 mM, EDTA 5 mM, pH 7.4) at 24-25°C for

1h. Non-specific binding was determined in the presence of 300 nM prazosin. The incubation was terminated by vacuum filtration over GF/B fibre filters. The filters were then washed with ice cold 50mM Tris HCl buffer (pH 7.4). The filtermats were dried and bound radioactivity retained on filters was counted.The IC_{50} & Kd were estimated by using the non-linear curve fitting program using G Pad Prism software. The value of inhibition constant Ki was calculated from competitive binding studies by using Cheng & Prusoff equation *(Cheng & Prusoff, Biochem Pharmacol, 1973,22: 3099-3108)*, Ki = IC_{50} /(1+L/Kd) where L is the concentration of [^{3}H]prazosin used in the particular experiment (Table I).

In Vitro Functional Studies

In order to study selectivity of action of these compounds towards different α-adrenoceptor subtypes, the ability of these compounds to antagonise α_1 – adrenoceptor agonist induced contractile response on aorta (α_{1D}prostate (α_{1A} and spleen ($\alpha_{1B}$was studied. Aorta and spleen tissues were isolated from urethane anaesthetised (1.5gm/kg) male wistar rats. Isolated tissues were mounted in organ bath containing Krebs Henseleit buffer of following composition (mM) : NaCl 118; KCl 4.7; $CaCl_2$ 2.5; $MgSO_4$. $7H_2O$ 1.2; $NaHCO_3$ 25; $KH_2PO_4$1.2; glucose 11.5. Buffer was maintained at 37°C and aereated with a mixture of 95% O_2 and 5% CO_2. A resting tension of 2g (aorta) or 1g (spleen and prostate)was applied to tissues .Contractile response was monitored using a force displacement transducer and recorded on chart recorders. Tissues were allowed to equilibrate for 2 hours. At the end

of equilibration period, concentration response curves to norepinephrine (aorta) and phenylepinephrine (spleen and prostate) were obtained in absence and presence of tested compound (at concentration of 0.1,1 and 10 mM). Antagonist affinity was calculated and expressed as pK_B vales in Table II.

In Vivo Uroselectivity Study:

In order to assess the uroselectivity in vivo, the effects of these compounds were studied on mean arterial pressure (MAP) and intraurethral pressure (IUP) in conscious beagle dogs as per the method of Brune et. al. (*Pharmacol 1996, 53 :356-368*). Briefly, male dogs were instrumented for chronic continuous measurement of arterial blood pressure by implanting a telemetry transmitter (TL11M2-D70-PCT, Data Sci. International, St. Paul, MN. USA) into the femoral artery, two weeks prior to the study. During the recovery period, the animal was acclimatized to stay in the sling restraint. On the day of testing, overnight fasted animal was placed in the sling restraint. A Swan-Ganz. Balloon tipped catheter was introduced into the urethra at the level of prostate and the balloon was inflated (Brune. et. al. 1996). After recording the base line readings, effect of 16 µg/kg, phenylephrine (i.v.) on MAP and IUP was recorded. The response of phenylephrine to MAP and IUP were recorded at 0.5, 1, 2, 3, 4, 6, 9 and 24 hours after the oral administration of vehicle or the test drug. The changes in MAP was recorded on line using Dataquest Software (Data Sci. International. St. Paul, MN. USA) and IUP was recorded on a Grass Polygraph (Model 7, Grass Instruments, USA). The change in phenylephrine response on MAP and IUP administration after the

test drug administration was calculated as percent change of that of control values. Area under curve was calculated and the ratio of the values for MAP and IUP was used for calculating the uroselectivity (Table III)

Table I: Radioligand Binding Studies

Affinity of compounds for Alpha –1 adrenoreceptor subtypes.

Compound No.	α_{1A} (Rat submaxillary)	α_{1B} (Rat liver)	Selectivity α_{1B}/α_{1A}
	Ki (nM)	Ki (nM)	
01	0.8	73	91
02	83	398	4.8
03	32.5	168	5
04	80	363	4.5
05	259	>500	2
06.	36	469	13
07	183	>500	2.7
08	0.34	29	85
09	0.3	62	207
10	62	165	2.7
11	0.13	19	146
12	8.66	51.3	5.9
13	6.3	384	61
14	>500	>500	1
15	>500	>500	1
16	>500	>500	1
17	48	37	0.78
18	10	271	27
19	5.26	81	15
20	46.8	>500	'11
21	>500	>500	1
22	208	>500	2.4
23	0.16	28	175
24	0.24	28	117
25	3.3	>500	>151
26	38	>500	13
27	>500	>500	1
28	>500	>500	1
29	3.45	708	205
30	48	611	13
31	2.1	232	110

Table II:

In Vitro Functional Assays:

Compound No.	α Adrenoceptor Subtype (pK_B)			Selectivity	
	α_{1A}	α_{1B}	α_{1D}	α_{1A}/α_{1D}	α_{1A}/α_{1B}
01	9.27	7.66	8.64	4	41
08	8.93	8.40	9.05	-1.31	3.4
09	9.17	7.8	8.6	3.6	23
11	9.95	8.28	8.76	15	47
13	8.04	6.09	7.29	5.6	89
23	9.94	7.71	9.91	1	170
24	10.4	7.85	9.27	13	355
25	8.90	7.17	9.00	-1.26	54
29	7.06	5.8	7.47	-2.57	18
31	8.3	ND	7.79	3.24	

Table III: In Vivo Uroselectivity Studies in Conscious Beagle Dogs

Compound No.	Dose (µg/kg)	Route	Area Under Curve		Uroselectivity Ratio
			MAP	IUP	IUP/MAP
01	100	p.o	93	514	5.54
11	10	p.o	10	661	66
23	3	p.o	197	790	4
24	3	p.o.	68	522	7.6

While the present invention has been described in terms of its specific embodiments, certain modifications and equivalents will be apparent to those skilled in the art and are intended to be included within the scope of the present invention.

WE CLAIM:

1. A compound having the structure of Formula I



FORMULA - I

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl,

2. The compound according to claim 1 wherein halogen is selected from the group consisting of chloro, fluoro, iodo; C_1-C_6 alkyl is selected from the group consisting of methyl, ethyl, n-propyl, isopropyl, butyl, tert-butyl, and C_1-C_6 alkoxy is selected from the group consisting of methoxy, ethoxy, n-propoxy, isopropoxy, and hexyloxy.

3. The compounds according to claim 1 selected from the group consisting of:

- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 01).
- 2-[3-{4-(3-Chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 02).
- 2-[3-{4-(2-Methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 03).

- 2-[3-{4-(4-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 04).

- 2-[3-{4-(3-Trifluoromethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 05).

- 2-[3-{4-(2-Fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 06).

- 2-[3-{4-(3,4-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 07).

- 2-[3-{4-(2-Methoxy-5-fluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 08).

- 2-[3-{4-(2-Ethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 09).

- 2-[3-{4-(2,4-Difluorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 10).

- 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 11).

- 2-[3-{4-(2-Methyl-5-chlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 12).

- 2-[3-{4-(Phenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 13).

- 2-[3-{4-(Benzyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 14).

- 2-[3-{4-(Cinnamyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 15).

- 2-[3-{4-(4-Nitrophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 16).

- 2-[3-{4-(3-Chloro-4-methylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 17).

- 2-[3-{4-(4-Fluoro-2-methoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 18).

- 2-[3-{4-(Bis-4-fluorophenyl)methylpiperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 19).

- 2-[3-{4-(2,4-Dichlorophenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 20).

- 2-[3-{4-(2,4-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 21).
- 2-[3-{4-(2,6-Dimethylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 22).
- 2-[3-{4-(2-Isopropoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 23).
- 2-[3-{4-(2-Propoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 24).
- 2-[3-{4-(2-n-Hexyloxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 25).
- 2-[3-{4-(2,5-Dimethoxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 26).
- 2-[3-{4-(4-tert-Butylphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 27).
- 2-[3-{4-(2-Methoxy-6-hydroxyphenyl)piperazin-1-yl}propyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 28).
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 29).
- 2-[3-{4-(2-Methoxyphenyl)piperazin-1-yl}-2-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 30).
- 2-[3-{4-(2-Ethoxyphenyl)piperazin-1-yl}-3-methylpropyl]-3a,4,7,7a-tetrahydro-1H-isoindole-1,3(2H)-dione (Compound 31).

4. A method of selectively antagonizing α_1-adrenergic receptors in a mammal comprising administering to said mammal a compound having the structure of Formula I



FORMULA - I

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl.

5. A method for treating benign prostatic hyperplasia in a mammal comprising administering to said mammal a compound having the structure of Formula I



FORMULA - I

its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl.

6. A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutical acceptable carrier.

7. A method of selectively antagonizing α_1-adrenergic receptors in a mammal comprising the step of administering to the said mammal the pharmaceutical composition according to claim 6.

8. A method for treating benign prostatic hyperplasia in a mammal comprising the step of administering to the said mammal the pharmaceutical composition according to claim 6.

9. A process for preparing a compound of Formula I



FORMULA - I

or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, whereIn A is a straight or branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group, or (dihalodiphenyl) methyl, which comprises reacting a compound of Formula II, with piperazine derivatives of Formula III, as shown in Scheme I wherein A and R are the same as defined above.

10. A process for preparing a compound of Formula I



FORMULA - I

or its pharmaceutically acceptable salts, amides, enantiomers, diastereomers, N-oxides, prodrugs, metabolites or their polymorphs, wherein A is a straight or

branched C_1-C_4 alkyl chain; R is cinnamyl, benzyl, substituted benzyl, phenyl, mono- or disubstituted phenyl group substituted with the substituents independently selected from the group consisting of halogen, hydroxy, C_1-C_6 alkyl, C_1-C_6 alkoxy, trifluoromethyl, nitro, trifluoroalkoxy group or (dihalodiphenyl) methyl, which comprises reacting 1-(ω-haloalkyl)cis-3a,4,7,7a-tetrahydrophthalimide of Formula IV, wherein A is the same as defined above, with a compound of Formula V, wherein R is the same as defined above, as shown in Scheme II.

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/IB 01/02261

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C07D209/48 A61K31/40 A61P13/08

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C07D A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)
CHEM ABS Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	U. V. KRGAONKAR ET AL.: "Synthesis of N-'3-(4-Aryl-1-piperazinyl)propyl!-4,4-bis (4-methoxyphenyl)piperidin-2,6-diones/Tetr ahydrophthalimides/Camphorimides as Sedatives" J. INDIAN. CHEM. SOC., vol. LX, no. 9, 1983, pages 874-876, XP001062943 cited in the application table 1 ---	1,2
X	R. N. ZAGIDULLIN: "N-(.beta.-Aminoethyl)piperazine and its derivatives in aminomethylation reactions" ZH. OBSHCH. KHIM., vol. 61, no. 1, 1991, pages 247-253, XP001062785 * compound of formula VIIIb * --- -/--	1,2

[X] Further documents are listed in the continuation of box C. [X] Patent family members are listed in annex.

* Special categories of cited documents:

'A' document defining the general state of the art which is not considered to be of particular relevance
'E' earlier document but published on or after the international filing date
'L' document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
'O' document referring to an oral disclosure, use, exhibition or other means
'P' document published prior to the international filing date but later than the priority date claimed

'T' later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
'X' document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
'Y' document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
'&' document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
18 April 2002	03/05/2002

Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Herz, C

Form PCT/ISA/210 (second sheet) (July 1992)

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/IB 01/02261

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
Y	US 6 090 809 A (N. ANAND ET AL.) 18 July 2000 (2000-07-18) cited in the application claims 1-8	1-10
Y	US 6 083 950 A (N. ANAND ET AL.) 4 July 2000 (2000-07-04) cited in the application claims 1-8	1-10
A	WO 98 51298 A (ORTHO-MCNEIL PHARMACEUTICAL INC.) 19 November 1998 (1998-11-19) claims 1-25	1-10
A	EP 0 711 757 A (F. HOFFMANN-LA ROCHE AG) 15 May 1996 (1996-05-15) claims 1-22	1-10
X	R. N. ZAGIDULLIN: "N-(.beta.)-Ethylaminopiperazine) and its derivatives in a Mannich reaction" KHIM. VYSOKOMOL. SOEDIN. NEFTEKHIM., 1973, pages 44-45, XP001062241 * compounds of formula 14 *	1,2
A	B. KENNY ET AL.: "Pharmacological Options in the Treatment of Benign Prostatic Hyperplasia" J. MED. CHEM., vol. 40, no. 9, 1997, pages 1293-1315, XP002195160 tables 3-17	1-10
A	AT 387 773 B (BRISTOL-MEYERS CO.) 10 March 1989 (1989-03-10) claims 1-14	1-10
A	US 4 524 206 A (J. S. NEW, J. P. YEVICH) 18 June 1985 (1985-06-18) cited in the application claims 1-23	1-10
A	US 4 479 954 A (N. HIROSE ET AL.) 30 October 1984 (1984-10-30) claims 1-43	1-10
A	US 4 598 078 A (K. ISHIZUMI ET AL.) 1 July 1986 (1986-07-01) cited in the application claims 1-18	1-10
A	EP 0 109 562 A (SUMITOMO CHEMICAL CO., LTD.) 30 May 1984 (1984-05-30) claims 1-7	1-10

-/--

INTERNATIONAL SEARCH REPORT

Inter nal Application No
PCT/IB 01/02261

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP 0 111 226 A (EISAI CO., LTD.) 20 June 1984 (1984-06-20) claims 1-42	1-10
A	PATENT ABSTRACTS OF JAPAN vol. 008, no. 126, 13 June 1984 (1984-06-13) & JP 59 036661 A (EISAI CO., LTD.) abstract	1-10

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte inal Application No
PCT/IB 01/02261

Patent document cited in search report		Publication date	Patent family member(s)		Publication date
US 6090809	A	18-07-2000	US	6083950 A	04-07-2000
			AU	1979799 A	14-02-2000
			AU	4641099 A	14-02-2000
			BR	9912318 A	02-05-2001
			CN	1318052 T	17-10-2001
			CZ	20010235 A3	15-08-2001
			EP	1097134 A1	09-05-2001
			HU	0102980 A2	28-12-2001
			WO	0005206 A1	03-02-2000
			WO	0005205 A1	03-02-2000
			PL	345562 A1	17-12-2001
			SK	932001 A3	06-08-2001
US 6083950	A	04-07-2000	US	6090809 A	18-07-2000
WO 9851298	A	19-11-1998	AU	7366998 A	08-12-1998
			BR	9809804 A	27-06-2000
			CN	1264300 T	23-08-2000
			EP	0984777 A1	15-03-2000
			HU	0100048 A2	30-07-2001
			NO	995518 A	11-01-2000
			PL	342518 A1	18-06-2001
			TR	9902971 T2	21-03-2001
			US	6071915 A	06-06-2000
			WO	9851298 A1	19-11-1998
			US	6303594 B1	16-10-2001
			ZA	9803968 A	11-11-1999
EP 711757	A	15-05-1996	US	5688795 A	18-11-1997
			AU	3459995 A	16-05-1996
			BR	9505107 A	09-09-1997
			CA	2162089 A1	09-05-1996
			CN	1136039 A	20-11-1996
			CZ	9502910 A3	11-09-1996
			EP	0711757 A1	15-05-1996
			FI	955376 A	09-05-1996
			HU	73843 A2	30-09-1996
			JP	8208614 A	13-08-1996
			NO	954453 A	09-05-1996
			NZ	280396 A	26-05-1997
			PL	311261 A1	13-05-1996
			SG	70950 A1	21-03-2000
			TR	960469 A2	21-07-1996
AT 387773	B	10-03-1989	US	4524206 A	18-06-1985
			AT	291584 A	15-08-1988
			AU	581858 B2	09-03-1989
			AU	3287084 A	30-05-1985
			BE	900555 A1	11-03-1985
			CA	1285564 A1	02-07-1991
			CH	660484 A5	30-04-1987
			CS	8406721 A2	17-12-1987
			CS	8507792 A2	17-12-1987
			CY	1538 A	16-11-1990
			DD	224593 A5	10-07-1985
			DE	3433327 A1	28-03-1985
			DK	171990 B1	08-09-1997
			ES	535780 D0	01-04-1986

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter nal Application No
PCT/IB 01/02261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
AT 387773 B		ES 8605797 A1	16-09-1986
		FI 843522 A ,B,	13-03-1985
		FR 2555585 A1	31-05-1985
		GB 2146333 A ,B	17-04-1985
		GR 80320 A1	14-01-1985
		HK 84590 A	25-10-1990
		HU 36116 A2	28-08-1985
		IE 58020 B1	30-06-1993
		IL 72854 A	31-03-1988
		IT 1196250 B	16-11-1988
		JP 1922135 C	07-04-1995
		JP 6047586 B	22-06-1994
		JP 60084282 A	13-05-1985
		KR 8900566 B1	21-03-1989
		LU 85537 A1	29-04-1985
		NL 8402769 A	01-04-1985
		NO 843579 A ,B	13-03-1985
		NZ 209480 A	08-01-1988
		OA 7809 A	20-11-1986
		PT 79187 A ,B	01-10-1984
		SE 463368 B	12-11-1990
		SE 8404552 A	13-03-1985
		SU 1384199 A3	23-03-1988
		YU 156384 A1	28-02-1987
		YU 210386 A1	31-12-1987
		ZA 8407065 A	24-04-1985
US 4524206 A	18-06-1985	AT 387773 B	10-03-1989
		AT 291584 A	15-08-1988
		AU 581858 B2	09-03-1989
		AU 3287084 A	30-05-1985
		BE 900555 A1	11-03-1985
		CA 1285564 A1	02-07-1991
		CH 660484 A5	30-04-1987
		CS 8406721 A2	17-12-1987
		CS 8507792 A2	17-12-1987
		CY 1538 A	16-11-1990
		DD 224593 A5	10-07-1985
		DE 3433327 A1	28-03-1985
		DK 171990 B1	08-09-1997
		ES 535780 D0	01-04-1986
		ES 8605797 A1	16-09-1986
		FI 843522 A ,B,	13-03-1985
		FR 2555585 A1	31-05-1985
		GB 2146333 A ,B	17-04-1985
		GR 80320 A1	14-01-1985
		HK 84590 A	25-10-1990
		HU 36116 A2	28-08-1985
		IE 58020 B1	30-06-1993
		IL 72854 A	31-03-1988
		IT 1196250 B	16-11-1988
		JP 1922135 C	07-04-1995
		JP 6047586 B	22-06-1994
		JP 60084282 A	13-05-1985
		KR 8900566 B1	21-03-1989
		LU 85537 A1	29-04-1985
		NL 8402769 A	01-04-1985
		NO 843579 A ,B	13-03-1985

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inte nal Application No
PCT/IB 01/02261

Patent document cited in search report	Publication date	Patent family member(s)		Publication date
US 4524206 A		NZ	209480 A	08-01-1988
		OA	7809 A	20-11-1986
		PT	79187 A ,B	01-10-1984
		SE	463368 B	12-11-1990
		SE	8404552 A	13-03-1985
		SU	1384199 A3	23-03-1988
		YU	156384 A1	28-02-1987
		YU	210386 A1	31-12-1987
		ZA	8407065 A	24-04-1985
US 4479954 A	30-10-1984	JP	1603541 C	04-04-1991
		JP	2029671 B	02-07-1990
		JP	57197265 A	03-12-1982
		BE	893378 A1	01-12-1982
		CA	1211436 A1	16-09-1986
		CH	649287 A5	15-05-1985
		DE	3220262 A1	16-12-1982
		DK	241982 A	30-11-1982
		ES	512642 D0	01-09-1983
		ES	8308548 A1	01-12-1983
		ES	523205 D0	16-02-1985
		ES	8503343 A1	01-06-1985
		ES	537721 D0	16-10-1985
		ES	8601156 A1	16-02-1986
		FR	2506771 A1	03-12-1982
		GB	2101590 A ,B	19-01-1983
		IT	1151781 B	24-12-1986
		KR	8701027 B1	25-05-1987
		KR	8800450 B1	06-04-1988
		KR	8800451 B1	06-04-1988
		NL	8202173 A	16-12-1982
		PH	19837 A	22-07-1986
		PH	19291 A	04-03-1986
		PH	19276 A	21-02-1986
		PH	19272 A	21-02-1986
		SE	450894 B	10-08-1987
		SE	8203272 A	30-11-1982
US 4598078 A	01-07-1986	JP	1639107 C	18-02-1992
		JP	3004069 B	22-01-1991
		JP	59076059 A	28-04-1984
		AT	29255 T	15-09-1987
		CA	1230597 A1	22-12-1987
		DE	3373306 D1	08-10-1987
		EP	0109562 A1	30-05-1984
EP 109562 A	30-05-1984	JP	1639107 C	18-02-1992
		JP	3004069 B	22-01-1991
		JP	59076059 A	28-04-1984
		AT	29255 T	15-09-1987
		CA	1230597 A1	22-12-1987
		DE	3373306 D1	08-10-1987
		EP	0109562 A1	30-05-1984
		US	4598078 A	01-07-1986
EP 111226 A	20-06-1984	JP	1720039 C	14-12-1992
		JP	4009782 B	21-02-1992
		JP	59095267 A	01-06-1984

INTERNATIONAL SEARCH REPORT

Information on patent family members

Inter ınal Application No
PCT/IB 01/02261

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 111226 A		AT 29716 T	15-10-1987
		CA 1257596 A1	18-07-1989
		DE 3373652 D1	22-10-1987
		EP 0111226 A1	20-06-1984
		US 4567180 A	28-01-1986
JP 59036661 A	28-02-1984	NONE	